Chargement en cours...

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer

BACKGROUND: Several recent randomized controlled trials (RCTs) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) have demonstrated significant improvements in progression-free survival (PFS); however, few have reported improv...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Breast Cancer (Dove Med Press)
Auteurs principaux: Forsythe, Anna, Chandiwana, David, Barth, Janina, Thabane, Marroon, Baeck, Johan, Tremblay, Gabriel
Format: Artigo
Langue:Inglês
Publié: Dove Medical Press 2018
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5942170/
https://ncbi.nlm.nih.gov/pubmed/29765247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S162841
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!